<DOC>
	<DOCNO>NCT00118755</DOCNO>
	<brief_summary>This 2-arm study evaluate efficacy safety 2 different treatment schedule oral Xeloda intravenous ( IV ) Eloxatin ( oxaliplatin ) IV bevacizumab ( Avastin ) first-line treatment patient locally advance metastatic colorectal cancer . Patients randomize receive either : 1 ) Xeloda 850 mg/m^2 orally twice day ( po bid ) Days 1-14 , oxaliplatin 130 mg/m^2 IV Day 1 , Avastin 7.5 mg/kg IV Day 1 3-week cycle ; 2 ) Xeloda 1500 mg/m^2 po bid Days 1-7 , oxaliplatin 85 mg/m^2 IV Day 1 Avastin 5 mg/kg IV Day 1 2-week cycle . The anticipated time study treatment 1-2 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Two Different Schedules Xeloda ( Capecitabine ) First Line Therapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Metastatic inoperable locally advanced colorectal cancer &gt; =1 measurable target lesion Previous systemic therapy advance metastatic disease Previous treatment bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>